156 related articles for article (PubMed ID: 30903640)
61. Identification of a novel aFGF-binding peptide with anti-tumor effect on breast cancer from phage display library.
Dai X; Cai C; Xiao F; Xiong Y; Huang Y; Zhang Q; Xiang Q; Lou G; Lian M; Su Z; Zheng Q
Biochem Biophys Res Commun; 2014 Mar; 445(4):795-801. PubMed ID: 24530908
[TBL] [Abstract][Full Text] [Related]
62. Characterization of antilytic peptide antibody: application for the detection of lytic-based hybrid peptide in serum samples.
Ohara K; Horibe T; Kohno M; Kawakami K
J Pept Sci; 2011 Jul; 17(7):493-8. PubMed ID: 21351323
[TBL] [Abstract][Full Text] [Related]
63. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers.
Gaowa A; Horibe T; Kohno M; Tabata Y; Harada H; Hiraoka M; Kawakami K
Eur J Pharm Biopharm; 2015 May; 92():228-36. PubMed ID: 25801495
[TBL] [Abstract][Full Text] [Related]
64. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2.
Kasaian MT; Raible D; Marquette K; Cook TA; Zhou S; Tan XY; Tchistiakova L
J Immunol; 2011 Jul; 187(1):561-9. PubMed ID: 21622864
[TBL] [Abstract][Full Text] [Related]
65. Enhanced expression of the decoy receptor IL-13Ralpha2 in macrophages of Schistosoma japonicum-infected mice.
Wang W; Shen YX; Li J; Zhang SH; Luo QL; Zhong ZR; Jiang ZJ; Shen JL
Chin Med J (Engl); 2009 Jul; 122(14):1650-4. PubMed ID: 19719966
[TBL] [Abstract][Full Text] [Related]
66. Expression of human IL-13 receptor alpha2 extracellular domain in Pichia pastoris.
Ohkuri T; Takeda C; Yoshida Y; Izuhara K; Imoto T; Ueda T
Protein Expr Purif; 2007 Nov; 56(1):48-53. PubMed ID: 17604644
[TBL] [Abstract][Full Text] [Related]
67. Construction and application of elastin like polypeptide containing IL-4 receptor targeting peptide.
Sarangthem V; Cho EA; Bae SM; Singh TD; Kim SJ; Kim S; Jeon WB; Lee BH; Park RW
PLoS One; 2013; 8(12):e81891. PubMed ID: 24339977
[TBL] [Abstract][Full Text] [Related]
68. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
69. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
[TBL] [Abstract][Full Text] [Related]
70. Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.
Kawakami K
Curr Gene Ther; 2005 Apr; 5(2):213-23. PubMed ID: 15853729
[TBL] [Abstract][Full Text] [Related]
71. Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models.
Watanabe T; Ohtani T; Aihara M; Ishiuchi S
J Neurosurg; 2013 Apr; 118(4):838-45. PubMed ID: 23311938
[TBL] [Abstract][Full Text] [Related]
72. Adenoviral vector-mediated gene transfer of IL-13Ralpha2 chain followed by IL-13 cytotoxin treatment offers potent targeted therapy for cytotoxin-resistant cancers.
Saito M; Murata T; Watanabe K; Kawakami K; Suzuki M; Koji T; Puri RK; Kitazato K; Kobayashi N
Int J Cancer; 2005 Aug; 116(1):1-8. PubMed ID: 15756691
[TBL] [Abstract][Full Text] [Related]
73. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
74. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
75. Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide.
Jannoo R; Walker W; Kanamarlapudi V
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345109
[TBL] [Abstract][Full Text] [Related]
76. Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma.
Kikuchi O; Ohashi S; Horibe T; Kohno M; Nakai Y; Miyamoto S; Chiba T; Muto M; Kawakami K
Sci Rep; 2016 Mar; 6():22452. PubMed ID: 26956916
[TBL] [Abstract][Full Text] [Related]
77. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide.
Du B; Han H; Wang Z; Kuang L; Wang L; Yu L; Wu M; Zhou Z; Qian M
Mol Cancer Res; 2010 Feb; 8(2):135-44. PubMed ID: 20145035
[TBL] [Abstract][Full Text] [Related]
78. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
79. Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.
Ou W; Marino MP; Suzuki A; Joshi B; Husain SR; Maisner A; Galanis E; Puri RK; Reiser J
Hum Gene Ther Methods; 2012 Apr; 23(2):137-47. PubMed ID: 22612657
[TBL] [Abstract][Full Text] [Related]
80. IL-13Rα2 gene expression is a biomarker of adverse outcome in patients with adrenocortical carcinoma.
Kumar A; Bellayr IH; Singh HS; Puri RK
PLoS One; 2021; 16(2):e0246632. PubMed ID: 33591997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
